BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mahil SK, Bechman K, Raharja A, Domingo-Vila C, Baudry D, Brown MA, Cope AP, Dasandi T, Graham C, Lechmere T, Malim MH, Meynell F, Pollock E, Seow J, Sychowska K, Barker JN, Norton S, Galloway JB, Doores KJ, Tree TIM, Smith CH. The effect of methotrexate and targeted immunosuppression on humoral and cellular immune responses to the COVID-19 vaccine BNT162b2: a cohort study. Lancet Rheumatol 2021;3:e627-37. [PMID: 34258590 DOI: 10.1016/S2665-9913(21)00212-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Obeid M, Suffiotti M, Pellaton C, Bouchaab H, Cairoli A, Salvadé V, Stevenel C, Hottinger R, Pythoud C, Coutechier L, Molinari L, Trono D, Ribi C, Gottardo R, Fenwick C, Pascual M, Duchosal MA, Peters S, Pantaleo G. Humoral Responses Against Variants of Concern by COVID-19 mRNA Vaccines in Immunocompromised Patients. JAMA Oncol 2022. [PMID: 35271706 DOI: 10.1001/jamaoncol.2022.0446] [Reference Citation Analysis]
2 Garcillán B, Salavert M, Regueiro JR, Díaz-castroverde S. Response to Vaccines in Patients with Immune-Mediated Inflammatory Diseases: A Narrative Review. Vaccines 2022;10:297. [DOI: 10.3390/vaccines10020297] [Reference Citation Analysis]
3 Lupo-stanghellini MT, Di Cosimo S, Costantini M, Monti S, Mantegazza R, Mantovani A, Salvarani C, Zinzani PL, Inglese M, Ciceri F, Apolone G, Ciliberto G, Baldanti F, Morrone A, Sinno V, Locatelli F, Notari S, Turola E, Giannarelli D, Silvestris N. mRNA-COVID19 Vaccination Can Be Considered Safe and Tolerable for Frail Patients. Front Oncol 2022;12:855723. [DOI: 10.3389/fonc.2022.855723] [Reference Citation Analysis]
4 Sakuraba A, Luna A, Micic D. Serologic Response to Coronavirus Disease 2019 (COVID-19) Vaccination in Patients With Immune-Mediated Inflammatory Diseases: A Systematic Review and Meta-analysis. Gastroenterology 2022;162:88-108.e9. [PMID: 34599933 DOI: 10.1053/j.gastro.2021.09.055] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
5 Connolly CM, Paik JJ. Impact of methotrexate on first-dose COVID-19 mRNA vaccination. Lancet Rheumatol 2021;3:e607-9. [PMID: 34258589 DOI: 10.1016/S2665-9913(21)00217-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
6 De Santis M, Motta F, Isailovic N, Clementi M, Criscuolo E, Clementi N, Tonutti A, Rodolfi S, Barone E, Colapietro F, Ceribelli A, Vecellio M, Luciano N, Guidelli G, Caprioli M, Rezk C, Canziani L, Azzolini E, Germagnoli L, Mancini N, Lleo A, Selmi C. Dose-Dependent Impairment of the Immune Response to the Moderna-1273 mRNA Vaccine by Mycophenolate Mofetil in Patients with Rheumatic and Autoimmune Liver Diseases. Vaccines 2022;10:801. [DOI: 10.3390/vaccines10050801] [Reference Citation Analysis]
7 Firinu D, Perra A, Campagna M, Littera R, Fenu G, Meloni F, Cipri S, Sedda F, Conti M, Miglianti M, Costanzo G, Secci M, Usai G, Carta MG, Cappai R, Orrù G, Del Giacco S, Coghe F, Chessa L. Evaluation of antibody response to BNT162b2 mRNA COVID-19 vaccine in patients affected by immune-mediated inflammatory diseases up to 5 months after vaccination. Clin Exp Med 2021. [PMID: 34741188 DOI: 10.1007/s10238-021-00771-3] [Reference Citation Analysis]
8 Schreiber S, Ben-Horin S, Alten R, Westhovens R, Peyrin-Biroulet L, Danese S, Hibi T, Takeuchi K, Magro F, An Y, Kim DH, Yoon S, Reinisch W. Perspectives on Subcutaneous Infliximab for Rheumatic Diseases and Inflammatory Bowel Disease: Before, During, and After the COVID-19 Era. Adv Ther 2022. [PMID: 34988877 DOI: 10.1007/s12325-021-01990-6] [Reference Citation Analysis]
9 Lee ARYB, Wong SY, Chai LYA, Lee SC, Lee MX, Muthiah MD, Tay SH, Teo CB, Tan BKJ, Chan YH, Sundar R, Soon YY. Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis. BMJ 2022;376:e068632. [PMID: 35236664 DOI: 10.1136/bmj-2021-068632] [Reference Citation Analysis]
10 Sieiro Santos C, Calleja Antolin S, Moriano Morales C, Garcia Herrero J, Diez Alvarez E, Ramos Ortega F, Ruiz de Morales JG. Immune responses to mRNA vaccines against SARS-CoV-2 in patients with immune-mediated inflammatory rheumatic diseases. RMD Open 2022;8:e001898. [PMID: 34987093 DOI: 10.1136/rmdopen-2021-001898] [Reference Citation Analysis]
11 Venerito V, Stefanizzi P, Fornaro M, Cacciapaglia F, Tafuri S, Perniola S, Iannone F, Lopalco G. Immunogenicity of BNT162b2 mRNA SARS-CoV-2 vaccine in patients with psoriatic arthritis on TNF inhibitors. RMD Open 2022;8:e001847. [PMID: 34987092 DOI: 10.1136/rmdopen-2021-001847] [Reference Citation Analysis]
12 Grainger R, Kim AHJ, Conway R, Yazdany J, Robinson PC. COVID-19 in people with rheumatic diseases: risks, outcomes, treatment considerations. Nat Rev Rheumatol 2022. [PMID: 35217850 DOI: 10.1038/s41584-022-00755-x] [Reference Citation Analysis]
13 Lukaszuk K, Woclawek-Potocka I, Jakiel G, Malinowska P, Wdowiak A, Rozanska K, Rabalski L. Humoral Response to SARS-CoV-2 Vaccine of a Patient Receiving Methotrexate Treatment and Implications for the Need of Monitoring. Vaccines (Basel) 2021;9:1151. [PMID: 34696259 DOI: 10.3390/vaccines9101151] [Reference Citation Analysis]
14 Liew J, Gianfrancesco M, Harrison C, Izadi Z, Rush S, Lawson-Tovey S, Jacobsohn L, Ja C, Hyrich KL, Gossec L, Strangfeld A, Carmona L, Schäfer M, Frãzao-Mateus E, Bulina I, Stafford F, Tufan A, Graver C, Yardımcı GK, Zepa J, Al Emadi S, Cook C, Abutiban F, Dey D, Katigbak G, Kaufman L, Kowalski E, Martínez-Martínez MU, Patel NJ, Reyes-Cordero G, Salido E, Smith E, Snow D, Sparks J, Wise L, Bhana S, Gore-Massy M, Grainger R, Hausmann J, Sirotich E, Sufka P, Wallace Z, Machado PM, Robinson PC, Yazdany J. SARS-CoV-2 breakthrough infections among vaccinated individuals with rheumatic disease: results from the COVID-19 Global Rheumatology Alliance provider registry. RMD Open 2022;8:e002187. [PMID: 35387864 DOI: 10.1136/rmdopen-2021-002187] [Reference Citation Analysis]
15 Chen RE, Gorman MJ, Zhu DY, Carreño JM, Yuan D, VanBlargan LA, Burdess S, Lauffenburger DA, Kim W, Turner JS, Droit L, Handley SA, Chahin S, Deepak P, O'Halloran JA, Paley MA, Presti RM, Wu GF, Krammer F, Alter G, Ellebedy AH, Kim AHJ, Diamond MS. Reduced antibody activity against SARS-CoV-2 B.1.617.2 delta virus in serum of mRNA-vaccinated individuals receiving tumor necrosis factor-α inhibitors. Med (N Y) 2021;2:1327-1341.e4. [PMID: 34812429 DOI: 10.1016/j.medj.2021.11.004] [Reference Citation Analysis]
16 Salisbury H. Helen Salisbury: How's your appetite for risk? BMJ 2021;374:n1768. [PMID: 34257084 DOI: 10.1136/bmj.n1768] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Dopfer-Jablonka A, Steffens S, Müller F, Mikuteit M, Niewolik J, Cossmann A, Stankov MV, Behrens GMN, Hummers E, Heesen G, Schröder D, Roder S, Klawonn F, Vahldiek K, Hasenkamp J, Kallusky J, Falk CS, Overbeck TR, Heinemann S. SARS-CoV-2-specific immune responses in elderly and immunosuppressed participants and patients with hematologic disease or checkpoint inhibition in solid tumors: study protocol of the prospective, observational CoCo immune study. BMC Infect Dis 2022;22:403. [PMID: 35468758 DOI: 10.1186/s12879-022-07347-w] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Paley MA, Kim AHJ. B cells: more than just for antibodies in SARS-CoV-2 vaccine responses. Lancet Rheumatol 2021;3:e741-3. [PMID: 34514435 DOI: 10.1016/S2665-9913(21)00280-0] [Reference Citation Analysis]
19 Bonelli M, Mrak D, Tobudic S, Sieghart D, Koblischke M, Mandl P, Kornek B, Simader E, Radner H, Perkmann T, Haslacher H, Mayer M, Hofer P, Redlich K, Husar-Memmer E, Fritsch-Stork R, Thalhammer R, Stiasny K, Winkler S, Smolen JS, Aberle JH, Zeitlinger M, Heinz LX, Aletaha D. Additional heterologous versus homologous booster vaccination in immunosuppressed patients without SARS-CoV-2 antibody seroconversion after primary mRNA vaccination: a randomised controlled trial. Ann Rheum Dis 2022:annrheumdis-2021-221558. [PMID: 35027397 DOI: 10.1136/annrheumdis-2021-221558] [Reference Citation Analysis]
20 Mintoff D, Benhadou F. Guselkumab does not appear to influence the IgG antibody response to SARS-CoV-2. Dermatol Ther 2021;:e15246. [PMID: 34865295 DOI: 10.1111/dth.15246] [Reference Citation Analysis]
21 Ramirez GA, Asperti C, Cucca V, Yacoub MR. Challenges to Vaccination against SARS-CoV-2 in Patients with Immune-Mediated Diseases. Vaccines (Basel) 2021;9:1147. [PMID: 34696255 DOI: 10.3390/vaccines9101147] [Reference Citation Analysis]
22 Mahil SK, Bechman K, Raharja A, Domingo-Vila C, Baudry D, Brown MA, Cope AP, Dasandi T, Graham C, Khan H, Lechmere T, Malim MH, Meynell F, Pollock E, Sychowska K, Barker JN, Norton S, Galloway JB, Doores KJ, Tree T, Smith CH. Humoral and cellular immunogenicity to a second dose of COVID-19 vaccine BNT162b2 in people receiving methotrexate or targeted immunosuppression: a longitudinal cohort study. Lancet Rheumatol 2021. [PMID: 34778846 DOI: 10.1016/S2665-9913(21)00333-7] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Mangge H, Kneihsl M, Schnedl W, Sendlhofer G, Curcio F, Domenis R. Immune Responses against SARS-CoV-2-Questions and Experiences. Biomedicines 2021;9:1342. [PMID: 34680460 DOI: 10.3390/biomedicines9101342] [Reference Citation Analysis]
24 Lledó A, Retuerto M, Almendro-Vázquez P, Fernández-Ruiz M, Galindo M, Laguna-Goya R, Paz-Artal E, Lalueza A, Aguado JM, Pablos JL. SARS-CoV-2-specific T-cell responses after COVID-19 recovery in patients with rheumatic diseases on immunosuppressive therapy. Semin Arthritis Rheum 2021;51:1258-62. [PMID: 34775160 DOI: 10.1016/j.semarthrit.2021.10.006] [Reference Citation Analysis]
25 Arumahandi de Silva AN, Frommert LM, Albach FN, Klotsche J, Scholz V, Jeworowski LM, Schwarz T, Ten Hagen A, Zernicke J, Corman VM, Drosten C, Burmester GR, Biesen R. Pausing methotrexate improves immunogenicity of COVID-19 vaccination in elderly patients with rheumatic diseases. Ann Rheum Dis 2022:annrheumdis-2021-221876. [PMID: 35288376 DOI: 10.1136/annrheumdis-2021-221876] [Reference Citation Analysis]
26 Simader E, Tobudic S, Mandl P, Haslacher H, Perkmann T, Nothnagl T, Sautner J, Radner H, Winkler F, Burgmann H, Mrak D, Aletaha D, Winkler S, Blüml S. Importance of the second SARS-CoV-2 vaccination dose for achieving serological response in patients with rheumatoid arthritis and seronegative spondyloarthritis. Ann Rheum Dis 2021:annrheumdis-2021-221347. [PMID: 34844927 DOI: 10.1136/annrheumdis-2021-221347] [Reference Citation Analysis]
27 Hadjadj J, Planas D, Ouedrani A, Buffier S, Delage L, Nguyen Y, Bruel T, Stolzenberg M, Staropoli I, Ermak N, Macraigne L, Morbieu C, Henriquez S, Veyer D, Péré H, Casadevall M, Mouthon L, Rieux-laucat F, Chatenoud L, Schwartz O, Terrier B. Immunogenicity of BNT162b2 vaccine against the Alpha and Delta variants in immunocompromised patients with systemic inflammatory diseases. Ann Rheum Dis. [DOI: 10.1136/annrheumdis-2021-221508] [Reference Citation Analysis]
28 Li D, Xu A, Mengesha E, Elyanow R, Gittelman RM, Chapman H, Prostko JC, Frias EC, Stewart JL, Pozdnyakova V, Debbas P, Mujukian A, Horizon AA, Merin N, Joung S, Botwin GJ, Sobhani K, Figueiredo JC, Cheng S, Kaplan IM, McGovern DPB, Merchant A, Melmed GY, Braun J. The T-Cell Response to SARS-CoV-2 Vaccination in Inflammatory Bowel Disease is Augmented with Anti-TNF Therapy. Inflamm Bowel Dis 2022:izac071. [PMID: 35397000 DOI: 10.1093/ibd/izac071] [Reference Citation Analysis]
29 Body A, Ahern E, Lal L, Gillett K, Abdulla H, Opat S, O’brien T, Downie P, Turville S, Munier CML, Smith C, Macintyre CR, Segelov E. Protocol for SARS-CoV-2 post-vaccine surveillance study in Australian adults and children with cancer: an observational study of safety and serological and immunological response to SARS-CoV-2 vaccination (SerOzNET). BMC Infect Dis 2022;22. [DOI: 10.1186/s12879-021-07019-1] [Reference Citation Analysis]
30 Azzolini E, Pozzi C, Germagnoli L, Oresta B, Carriglio N, Calleri M, Selmi C, De Santis M, Finazzi S, Carlo-Stella C, Bertuzzi A, Motta F, Ceribelli A, Mantovani A, Bonelli F, Rescigno M. mRNA COVID-19 vaccine booster fosters B- and T-cell responses in immunocompromised patients. Life Sci Alliance 2022;5:e202201381. [PMID: 35169017 DOI: 10.26508/lsa.202201381] [Reference Citation Analysis]
31 Saleem B, Ross RL, Bissell LA, Aslam A, Mankia K, Duquenne L, Corsadden D, Carter C, Hughes P, Nadat FA, Mulipa P, Lobb M, Clarke B, Mbara K, Morton R, Dibb S, Chowdhury R, Newton D, Pike A, Kakkar V, Savic S, DelGaldo F, Emery P. Effectiveness of SARS-CoV-2 vaccination in patients with rheumatoid arthritis (RA) on DMARDs: as determined by antibody and T cell responses. RMD Open 2022;8:e002050. [PMID: 35365569 DOI: 10.1136/rmdopen-2021-002050] [Reference Citation Analysis]
32 Firinu D, Perra A, Campagna M, Littera R, Fenu G, Meloni F, Cipri S, Sedda F, Conti M, Miglianti M, Costanzo G, Secci M, Usai G, Carta MG, Cappai R, Orrù G, Del Giacco S, Coghe F, Chessa L. Evaluation of antibody response to BNT162b2 mRNA COVID-19 vaccine in patients affected by immune-mediated inflammatory diseases up to 5 months after vaccination. Clin Exp Med 2021. [PMID: 34741188 DOI: 10.1007/s10238-021-00771-3] [Reference Citation Analysis]
33 Choi E, Liew CF, Oon HH. Cutaneous adverse effects and contraindications to COVID-19 vaccination; four cases and an illustrative review from an Asian country. Dermatol Ther 2021;34:e15123. [PMID: 34478204 DOI: 10.1111/dth.15123] [Reference Citation Analysis]